Abstract describing significant results of crofelemer for cancer therapy-related diarrhea in breast cancer patients accepted for presentation at san antonio breast cancer symposium (sabcs)

Adult patients with breast cancer are a prespecified subgroup of the recently conducted ontarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) a second late-breaking abstract related to the ontarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at sabcs san francisco, ca / accesswire / november 4, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") family company napo pharmaceuticals ("napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase 3 ontarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on december 11, 2024 at the san antonio breast cancer symposium (sabcs). patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.
JAGX Ratings Summary
JAGX Quant Ranking